Our Oncology R&D

Stories of Caring

Our Oncology R&D

Oncology is one of five key areas of focus for Janssen Research & Development; it has become increasingly important in recent years with the launch of such important medicines as ZYTIGA® (abiraterone acetate) and IMBRUVICA® (ibrutinib). We invite you to view this short video featuring Peter F. Lebowitz, M.D., Ph.D., head of oncology research & development for Janssen R&D. In it, he describes the strategy behind our cancer drug development as well as our approach to partnerships, which was also featured in the Wall Street Journal in 2014.

NOTE REGARDING FORWARD-LOOKING STATEMENTS

This video contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995, including regarding product development. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, challenges and uncertainties inherent in product development, including the uncertainties of clinical success and the challenges in obtaining regulatory approvals. The viewer is cautioned not to rely on these forward-looking statements and should review the Annual Report on Form 10-K for the fiscal year ended December 28, 2014, including in Exhibit 99 thereto, for a further list and description of these risks, uncertainties and other factors. Neither Janssen nor Johnson & Johnson undertakes to update any forward-looking statements as a result of new information or future events or developments.